Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expression

BACKGROUND: Most patients with acute myeloid leukemia (AML) remain uncurable and require novel therapeutic methods. Gain-of-function FMS-like tyrosine kinase 3 (FLT3) mutations are present in 30–40% of AML patients and serve as an attractive therapeutic target. In addition, FLT3 is aberrantly expres...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Dengyang, Guo, Yao, Zhao, Yuming, Yu, Liuting, Chang, Zhiguang, Pei, Hanzhong, Huang, Junbin, Chen, Chun, Xue, Hongman, Xu, Xiaojun, Pan, Yihang, Li, Ningning, Zhu, Chengming, Zhao, Zhizhuang Joe, Yu, Jian, Chen, Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7948335/
https://www.ncbi.nlm.nih.gov/pubmed/33691697
http://dx.doi.org/10.1186/s12934-021-01559-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7948335/
https://www.ncbi.nlm.nih.gov/pubmed/33691697
http://dx.doi.org/10.1186/s12934-021-01559-6

Ejemplares similares